Abrdn Life Sciences Inves... (HQL)
NYSE: HQL
· Echtzeitkurs · USD
21.10
-0.05 (-0.24%)
Zum Schluss: Aug 14, 2026, 3:59 PM
21.10
+0.00%
Nachbörslich: 5:05 PM
Abrdn Life Sciences Investors (HQL) Stock Price, Analysis & Data
-0.24% (1D)
| Geld | 20.5 |
| Marktkapitalisierung | 641.61 Mio |
| Umsatz (TTM) | 1.11 Mio |
| Nettogewinn (TTM) | 198.17 Mio |
| Beta | 0.71 |
| EPS (ttm) | 6.64 |
| KGV (TTM) | 3.18 |
| Forward-KGV | n/a |
| KBV (TTM) | 1.14 |
| KUV (TTM) | 578.15 |
| Earnings Date | n/a |
| Brief | 21.45 |
| Volumen | 109,653 |
| Ø Vol. (20D) | 142,022 |
| Eröffnung | 21.09 |
| Vortagesschluss | 21.15 |
| Tagesspanne | 20.90 - 21.25 |
| 52-Wk Range | 13.57 - 21.42 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | $2.24 (10.62%) |
| Ex-Dividenden-Datum | 24. Aug. 2026 |
Über HQL
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture...
Branche Asset Management
Sektor Financial Services
IPO Datum May 1, 1992
Mitarbeiter n/a
Börse NYSE
Tickersymbol HQL
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Abrdn Life Sciences Investors 86.39 Mio, ein Rückgang von -0.35% im Vergleich zum Vorjahr (86.69 Mio). Der Gewinn lag bei 85.59 Mio, ein Anstieg von 0.35 %.
Finanzberichte